Synergy of molecular targeted approaches and immunotherapy in melanoma: Preclinical basis and clinical perspectives

Martina Sanlorenzo, Igor Vujic, Adrian Moy, Pietro Quaglino, Maria Teresa Fierro, Loretta Gammaitoni, Fabrizio Carnevale-Schianca, Massimo Aglietta, Dario Sangiolo

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Targeted therapy and immunotherapies are the novel pharmacologic treatment strategies for metastatic melanoma. BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response. The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma.Areas covered: We first review the effects of BRAF and MEK inhibitors on melanoma cells and on the different components of the immune system. Afterwards, we summarize the results of the preclinical and clinical studies that have combined targeted therapy and immunotherapy for the treatment of melanoma.Expert opinion: Clinical applications of immunotherapy strategies have recently changed the therapeutic mainstay for metastatic melanoma. Biologic and initial preclinical data support their integration with innovative molecular targeted therapies, opening enormous perspectives for researchers in the effort of finding a definitive cure. Main open challenges are the definition of reliable research models, assessment of effective schedules, safety issues and designing of personalized approaches.

Original languageEnglish
Pages (from-to)1491-1500
Number of pages10
JournalExpert Opinion on Biological Therapy
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

Keywords

  • BRAF inhibitors
  • immunotherapy
  • melanoma
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Fingerprint Dive into the research topics of 'Synergy of molecular targeted approaches and immunotherapy in melanoma: Preclinical basis and clinical perspectives'. Together they form a unique fingerprint.

Cite this